Tailoring Antibiotic Duration for Respiratory Tract Infections in Primary Care

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

About this trial

The rise of drug-resistant organisms and the need to minimize side effects calls for a new approach to antibiotic therapy duration. This study explores tailoring the length of antibiotic treatment to patient recovery, focusing on whether adjusting therapy based on when the patient feels better is as effective as completing the prescribed course for acute respiratory tract infections (RTIs). The investigators will enroll 474 outpatients aged 18-75 with acute RTIs across 25 Spanish healthcare centers. Patients will be randomized into two groups: one following standard full-course antibiotic therapy, and another receiving a tailored approach, where treatment may be shortened based on clinical assessments. The primary outcome is clinical efficacy at day 14. Secondary outcomes include antibiotic duration, complications, and quality of life.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Either adults with a) acute cough (new cough or worsening of a previous cough) as the predominant symptom which the clinician believes to be a bacterial acute lower RTI, such as community-acquired pneumonia, acute bronchitis or acute chronic obstructive pulmonary disease (COPD) exacerbations, or b) an acute bacterial rhinosinusitis

Doctors deem beta-lactam therapy (given every eight hours for a minimum of seven days) is necessary

Disqualifiers

RTIs different from a lower RTI or acute rhinosinusitis

Patients with suspected septicemia (quick Quick Sequential Organ Failure Assessment: respiratory rate ≥22 breaths/minute, systolic blood pressure <100 mm Hg or altered mental status with a Glasgow score < 5) ≥2

Patients with pneumonia and [Confusion, respiratory rate ≥30 breaths/minute, blood pressure < 90/60 mm Hg, or age >65 yr.] ≥1

Patients with very severe COPD (Forced Expiratory Volume in One Second <30%)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Tailoring the course duration to the patient's needs.

    Drug

    Patients will be advised to visit the center as soon as they feel better and are afebrile for a clinical assessment including vital signs (temperature, blood pressure, respiratory rate, pulse, and oxygen saturation) and C-reactive protein rapid testing after completing two full days of antibiotic.

  • Complete a 7-day course

    Drug

    The antibiotic course must be completed (7 days at least).

Treatment groups

474 Participants
are divided into 2 treatment groups
Group A: Control groupPlacebo comparator 1 intervention
Group B: Intervention groupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Clinical resolution

Number of patients with disappearance of fever, disappearance or improvement in overall condition (all scores \<2), such that no additional antimicrobial treatment is necessary.

Time frame
Day 14

Secondary outcomes

1

Duration of antibiotic therapy

Number of patients discontinuing treatment in both groups and what day they discontinue recorded

Time frame
Day 14
2

Doses taken

Number of doses of antibiotic taken

Time frame
Day 14
3

Duration of severe symptoms

Number of days until the last day the patient scores 5 in any of the symptoms in the RTI diary symptom

Time frame
Day 14
4

Duration of moderate symptoms

Number of days until the last day the patient scores 3 in any of the symptoms in the RTI symptom diary.

Time frame
Day 14

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: